142 related articles for article (PubMed ID: 23826842)
1. SABRE 1 (Surgery Against Brachytherapy - a Randomised Evaluation): feasibility randomised controlled trial (RCT) of brachytherapy vs radical prostatectomy in low-intermediate risk clinically localised prostate cancer.
Eccles BK; Cross W; Rosario DJ; Doble A; Parker C; Logue J; Little L; Stanton L; Bottomley D
BJU Int; 2013 Aug; 112(3):330-7. PubMed ID: 23826842
[TBL] [Abstract][Full Text] [Related]
2. Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT.
Hamdy FC; Elliott D; le Conte S; Davies LC; Burns RM; Thomson C; Gray R; Wolstenholme J; Donovan JL; Fitzpatrick R; Verrill C; Gleeson F; Singh S; Rosario D; Catto JW; Brewster S; Dudderidge T; Hindley R; Emara A; Sooriakumaran P; Ahmed HU; Leslie TA
Health Technol Assess; 2018 Sep; 22(52):1-96. PubMed ID: 30264692
[TBL] [Abstract][Full Text] [Related]
3. Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.
Hamdy FC; Donovan JL; Lane JA; Mason M; Metcalfe C; Holding P; Wade J; Noble S; Garfield K; Young G; Davis M; Peters TJ; Turner EL; Martin RM; Oxley J; Robinson M; Staffurth J; Walsh E; Blazeby J; Bryant R; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Gnanapragasam V; Hughes O; Kockelbergh R; Kynaston H; Paul A; Paez E; Powell P; Prescott S; Rosario D; Rowe E; Neal D
Health Technol Assess; 2020 Aug; 24(37):1-176. PubMed ID: 32773013
[TBL] [Abstract][Full Text] [Related]
4. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Wilkins A; Mossop H; Syndikus I; Khoo V; Bloomfield D; Parker C; Logue J; Scrase C; Patterson H; Birtle A; Staffurth J; Malik Z; Panades M; Eswar C; Graham J; Russell M; Kirkbride P; O'Sullivan JM; Gao A; Cruickshank C; Griffin C; Dearnaley D; Hall E
Lancet Oncol; 2015 Dec; 16(16):1605-16. PubMed ID: 26522334
[TBL] [Abstract][Full Text] [Related]
5. Radical prostatectomy versus deferred treatment for localised prostate cancer.
Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
[TBL] [Abstract][Full Text] [Related]
6. Phase II randomised control feasibility trial of a nutrition and physical activity intervention after radical prostatectomy for prostate cancer.
Hackshaw-McGeagh LE; Penfold C; Shingler E; Robles LA; Perks CM; Holly JMP; Rowe E; Koupparis A; Bahl A; Persad R; Shiridzinomwa C; Johnson L; Biernacka KM; Frankow A; Woodside JV; Gilchrist S; Oxley J; Abrams P; Lane JA; Martin RM
BMJ Open; 2019 Nov; 9(11):e029480. PubMed ID: 31699723
[TBL] [Abstract][Full Text] [Related]
7. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
8. A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy.
Lee WR; Hall MC; McQuellon RP; Case LD; McCullough DL
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):614-23. PubMed ID: 11597800
[TBL] [Abstract][Full Text] [Related]
9. Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: the Testing Radical prostatectomy in men with prostate cancer and oligo-Metastases to the bone (TRoMbone) trial.
Sooriakumaran P; Wilson C; Rombach I; Hassanali N; Aning J; D Lamb A; Cathcart P; Eden C; Ahmad I; Rajan P; Sridhar A; Bryant RJ; Elhage O; Cook J; Leung H; Soomro N; Kelly J; Nathan S; Donovan JL; Hamdy FC
BJU Int; 2022 Jul; 130(1):43-53. PubMed ID: 34878715
[TBL] [Abstract][Full Text] [Related]
10. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
11. Synthetic sling or artificial urinary sphincter for men with urodynamic stress incontinence after prostate surgery: the MASTER non-inferiority RCT.
Constable L; Abrams P; Cooper D; Kilonzo M; Cotterill N; Harding C; Drake MJ; Pardoe MN; McDonald A; Smith R; Norrie J; McCormack K; Ramsay C; Uren A; Mundy T; Glazener C; MacLennan G
Health Technol Assess; 2022 Aug; 26(36):1-152. PubMed ID: 35972773
[TBL] [Abstract][Full Text] [Related]
12. Low-dose rate brachytherapy for men with localized prostate cancer.
Peinemann F; Grouven U; Hemkens LG; Bartel C; Borchers H; Pinkawa M; Heidenreich A; Sauerland S
Cochrane Database Syst Rev; 2011 Jul; (7):CD008871. PubMed ID: 21735436
[TBL] [Abstract][Full Text] [Related]
13. NeuroSAFE robot-assisted laparoscopic prostatectomy versus standard robot-assisted laparoscopic prostatectomy for men with localised prostate cancer (NeuroSAFE PROOF): protocol for a randomised controlled feasibility study.
Dinneen E; Haider A; Allen C; Freeman A; Briggs T; Nathan S; Brew-Graves C; Grierson J; Williams NR; Persad R; Oakley N; Adshead JM; Huland H; Haese A; Shaw G
BMJ Open; 2019 Jun; 9(6):e028132. PubMed ID: 31189680
[TBL] [Abstract][Full Text] [Related]
14. Choice between prostatectomy and radiotherapy when men are eligible for both: a randomized controlled trial of usual care vs decision aid.
van Tol-Geerdink JJ; Willem Leer J; Weijerman PC; van Oort IM; Vergunst H; van Lin EN; Alfred Witjes J; Stalmeier PF
BJU Int; 2013 Apr; 111(4):564-73. PubMed ID: 22882966
[TBL] [Abstract][Full Text] [Related]
15. Permanent interstitial low-dose-rate brachytherapy for patients with localised prostate cancer: a systematic review of randomised and nonrandomised controlled clinical trials.
Peinemann F; Grouven U; Bartel C; Sauerland S; Borchers H; Pinkawa M; Heidenreich A; Lange S
Eur Urol; 2011 Nov; 60(5):881-93. PubMed ID: 21763066
[TBL] [Abstract][Full Text] [Related]
16. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study.
Yaxley JW; Coughlin GD; Chambers SK; Occhipinti S; Samaratunga H; Zajdlewicz L; Dunglison N; Carter R; Williams S; Payton DJ; Perry-Keene J; Lavin MF; Gardiner RA
Lancet; 2016 Sep; 388(10049):1057-1066. PubMed ID: 27474375
[TBL] [Abstract][Full Text] [Related]
17. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
Eastham JA; Kelly WK; Grossfeld GD; Small EJ;
Urology; 2003 Dec; 62 Suppl 1():55-62. PubMed ID: 14747042
[TBL] [Abstract][Full Text] [Related]
18. Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study).
Lane JA; Donovan JL; Young GJ; Davis M; Walsh EI; Avery KNL; Blazeby JM; Mason MD; Martin RM; Peters TJ; Turner EL; Wade J; Bollina P; Catto JWF; Doherty A; Gillatt D; Gnanapragasam V; Hughes O; Kockelbergh R; Kynaston H; Oxley J; Paul A; Paez E; Rosario DJ; Rowe E; Staffurth J; Neal DE; Hamdy FC; Metcalfe C;
BJU Int; 2022 Sep; 130(3):370-380. PubMed ID: 35373443
[TBL] [Abstract][Full Text] [Related]
19. A systematic review of randomised controlled trials of radiotherapy for localised prostate cancer.
Wolff RF; Ryder S; Bossi A; Briganti A; Crook J; Henry A; Karnes J; Potters L; de Reijke T; Stone N; Burckhardt M; Duffy S; Worthy G; Kleijnen J
Eur J Cancer; 2015 Nov; 51(16):2345-67. PubMed ID: 26254809
[TBL] [Abstract][Full Text] [Related]
20. Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received.
Neal DE; Metcalfe C; Donovan JL; Lane JA; Davis M; Young GJ; Dutton SJ; Walsh EI; Martin RM; Peters TJ; Turner EL; Mason M; Bryant R; Bollina P; Catto J; Doherty A; Gillatt D; Gnanapragasam V; Holding P; Hughes O; Kockelbergh R; Kynaston H; Oxley J; Paul A; Paez E; Rosario DJ; Rowe E; Staffurth J; Altman DG; Hamdy FC;
Eur Urol; 2020 Mar; 77(3):320-330. PubMed ID: 31771797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
